- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02596698
Mitochondrial Dysfunction, Inflammation, and White Matter Integrity in Youth With Mood Disorders
Study Overview
Status
Detailed Description
This is a research study looking at the biology of mood disorders in youth. The investigator ask participants to come in for three visits. The first visit includes a diagnostic interview, some questionnaires, and a blood draw. The blood draw will take place at the Fairview Outpatient Lab. A trained technician will take about 4 teaspoons of blood from the participant's arm. This sample will be sent to Dr. Andreazza in Toronto, Ontario for further analysis. No results will be shared with the participant.
The second visit would take place at the Fairview Riverside Ambulatory Research Center (ARC). This appointment will include the Trier Social Stress Test (TSST). For this, participants will be asked to prepare a short speech for 5 minutes and deliver that speech for in front of an audience with another task to follow. This task will be videotaped. After the participant has completed the speech task, the participant will be asked to complete a number of laptop games which will test for things like attention and memory. Participants will be asked to provide 5 saliva samples throughout the course of this visit so the investigators can look at Cortisol which is a hormone naturally found in saliva. The investigators will also ask participants to complete an additional set of 5 spit samples at home during the course of a normal day and bring those back to their next appointment.
The third visit would take place at the Center for Magnetic Resonance Research (CMRR) and would include a brain MRI. The MRI scan is noninvasive and takes about 2 hours. Participants will be asked to provide a urine sample and complete a urine toxicology screen (drug test) and pregnancy test (if female) prior to the MRI scan. Participants may not participate if drug or pregnancy testing is positive. The MRI involves taking pictures of the brain, from which measures of the integrity of certain brain tissues can be derived. For the scan, participants will be asked to lie down quietly on a scanner bed. Once they are inside the scanner, it will start to take pictures. While in the scanner, participants will be doing things like resting, or listening to music.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55454
- Ambulatory Research Center (ARC)
-
Minneapolis, Minnesota, United States, 55455
- Center for Magnetic Resonance Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria - All Participants:
- Age 13-18 years old
- Both child and guardian are English speaking
Inclusion Criteria - Patient Group:
- Has a diagnosis of a depressive disorder, a bipolar spectrum disorder (type 1, type 2, Unspecified), or an unspecified mood disorder based on the Diagnostic Statsitical Manual 5 (DSM-5)
Inclusion Criteria - Healthy Controls
- Does not meet criteria for any psychiatric disorders based on the DSM-5
- Does not have a family history of psychotic or mood disorders in first degree relative
Exclusion Criteria:
- Past history of brain damage, a seizure disorder, increased intracranial pressure, history of head trauma with loss of consciousness for >15 minutes, history of stroke, mental retardation, or other serious neurological disorder
- MRI contraindications such as braces, metal implants, implanted medical devices, or claustrophobia
- Intelligence quotient < 80
- Severe or acute medical illness
- A history of current (past 3 months) substance disorder (defined by DSM-5) with the exception of Nicotine
- Refusal to cooperate with study procedures
- Active suicidal ideation with intent
- Self-injury that requires medical attention (e.g. stitches) or gets significantly worse during the course of the study
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Adolescents with Mood Disorders
Teens aged 13-18 with a diagnosis of a mood disorder.
|
Adolescents with no Mental Health Diagnoses
13-18, no psychiatric d/o diagnosis
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood Analysis
Time Frame: Baseline
|
Blood samples will be analysed for mitochondrial dysfunction and resulting oxidative damage to lipids, and protein and messenger ribonucleic acid levels of inflammatory cytokines
|
Baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MRI Data
Time Frame: Up to 6 weeks after baseline
|
White matter integrity.
Diffusion imaging data will be processed, following registration and motion correction, using a probabilistic tractography approach that will define and extract parameters such as fractional anisotrophy and radial diffusion from fiber bundles of interest.
In this study we will focus on white matter tracts connecting fronto-limbic brain regions.
Details about the tractography procedures can be found at http://surfer.nmr.mgh.harvard.edu/fswiki/Tracula
|
Up to 6 weeks after baseline
|
Saliva Cortisol
Time Frame: Up to 6 weeks of baseline
|
Stress Functioning.
Saliva samples from the Trier Social Stress Test will be stored in a freezer and sent as a complete batch to Trier, Germany.
We will conduct repeated measures ANOVA tests on the cortisol data and examine group and group x time interactions.
We will calculate the Area Under the Curve for each person's pattern of cortisol responses over time, and these values will be used in multivariate regression analyses below.
|
Up to 6 weeks of baseline
|
Beck Depression Inventory (BDI-II)
Time Frame: Baseline and within 6 weeks of baseline
|
Measures levels of depression in participants.
Has information on suicidal ideation.
If participants are suicidal, a member of research staff will talk with the participant and develop a safety plan with the adolescent and their parent.
|
Baseline and within 6 weeks of baseline
|
Children's Depression Rating Scale - Revised (CDRS-R)
Time Frame: Baseline
|
Measures levels of depression in participants.
Has information on suicidal ideation.
If participants are suicidal, a member of research staff will talk with the participant and develop a safety plan with the adolescent and their parent.
|
Baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Kathryn R Cullen, MD, University of Minnesota
- Principal Investigator: Ana Andreazza, PhD, University of Toronto, Ontario
- Principal Investigator: Bonnie Klimes-Dougan, PhD, University of Minnesota
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1507M75201
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryActive, not recruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States